Duavee Compounded Equivalent: What Women Actually Need to Know in 2026

What Duavee Actually Is, and Why It Matters for Women With a Uterus

Duavee belongs to a category called a tissue-selective estrogen complex (TSEC). It pairs conjugated estrogens (CE), the estrogen component that relieves hot flashes and night sweats, with bazedoxifene (BZA), a selective estrogen receptor modulator (SERM) that protects the uterine lining. Because bazedoxifene performs the uterine-protective role, you do not take a separate progestogen. For women who experience progestogen-related side effects, such as bloating, mood shifts, or breast tenderness, that distinction can be meaningful.

The SMART trials, a series of phase III randomized controlled studies in postmenopausal women with an intact uterus, established that CE 0.45 mg / BZA 20 mg reduced moderate-to-severe vasomotor symptoms and protected the endometrium without progestogen over 12 months. The FDA granted approval in October 2013 specifically for this indication.

Who the FDA Says Duavee Is For

The FDA prescribing information specifies Duavee for:

• Moderate-to-severe vasomotor symptoms (hot flashes, night sweats) associated with menopause
• Prevention of postmenopausal osteoporosis, as a secondary indication

Both indications apply only to women who have a uterus. Women who have had a hysterectomy are not candidates because the bazedoxifene component exists specifically to protect the endometrium from unopposed estrogen.

How It Differs from Standard Estrogen-Progestogen Therapy

Standard combined hormone therapy pairs an estrogen with a progestogen (medroxyprogesterone acetate, norethindrone acetate, micronized progesterone, and others). Duavee substitutes the SERM bazedoxifene for the progestogen. A 2014 analysis published in the journal Menopause confirmed that BZA 20 mg provided endometrial safety equivalent to that seen with standard progestogen regimens over 12 months, with no cases of endometrial hyperplasia in the CE 0.45/BZA 20 group.

The Compounded Equivalent Question: What Is and Is Not Possible

This is probably the question most women arrive here with. The direct answer: there is no commercially available compounded equivalent to Duavee in the United States as of 2026.

Here is why.

Bazedoxifene Is Not a Standard Compounding Ingredient

Conjugated estrogens can be approximated in compounding (pharmacists sometimes use plant-derived conjugated equine estrogen fractions or estradiol as a substitute), but bazedoxifene is a different matter. Bazedoxifene is not on the FDA's bulk drug substances list for 503A or 503B compounding pharmacies, and it is not produced by any US compounding supplier in a finished API (active pharmaceutical ingredient) form suitable for compounding. Without bazedoxifene, you do not have a true Duavee equivalent.

The FDA's 503B outsourcing facility framework governs large-scale pharmacy compounding and publishes a list of bulk substances that may lawfully be used. Bazedoxifene does not appear on that list. A compounding pharmacy that claims to offer a Duavee equivalent should be asked specifically which API they are using for uterine protection, because if they are substituting micronized progesterone or another progestogen, that is a different drug combination, not an equivalent.

What About Compounded Conjugated Estrogens Alone?

Some clinicians do prescribe compounded CE-like preparations combined with a separate progestogen for women who want progestogen-free options but cannot afford Duavee. That is a clinically reasonable approach for some women, but it is not the same pharmacological combination. The SERM mechanism of bazedoxifene differs from progestogen receptor activity in ways that affect breast tissue, bone density, and endometrial response differently.

A practical framework for your clinician conversation:

| Goal | Duavee (CE/BZA) | CE + Progestogen alternative | |---|---|---| | Uterine protection without progestogen | Yes | No | | Avoiding progestogen side effects | Yes | No | | FDA-approved combination | Yes | Yes (separate components) | | Generic or compounded available | No | Yes (components can be compounded) | | Cost without assistance | ~$240/month | Variable; often lower | | Bone protection data | Yes (SMART-1 through SMART-5) | Yes (estradiol, CE separately) |

Life Stage Relevance: Perimenopause Through Postmenopause

Perimenopause

Duavee is approved for menopausal symptoms, and the FDA label uses the language "menopause" throughout. Perimenopausal women, meaning those still having irregular cycles but experiencing vasomotor symptoms, are not the primary studied population. The SMART trials enrolled women who were postmenopausal (defined as 12 months without a menstrual period) and aged 40 to 65.

If you are perimenopausal and still having cycles, your clinician may discuss whether your symptom burden warrants off-label use or whether a different therapy is more appropriate. Perimenopausal women also still need contraception, which complicates any hormone therapy decision (more on that below).

Early Postmenopause

This is the population with the strongest evidence base and the clearest indication. The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy affirms that for healthy women aged under 60 or within 10 years of menopause onset, the benefits of hormone therapy for symptom management generally outweigh risks. Duavee fits within that recommendation for women with a uterus who prefer a progestogen-free approach.

Late Postmenopause (More Than 10 Years After Final Menstrual Period)

Initiating any systemic hormone therapy more than 10 years after menopause or after age 60 carries a different risk-benefit calculation. Bazedoxifene's SERM activity theoretically offers cardiovascular neutrality compared to some progestogens, but long-term data beyond the 12-month SMART trial windows are limited. This is an area where the evidence gap is real and where your clinician should individualize the decision.

Pregnancy, Lactation, and Contraception

Duavee is contraindicated in pregnancy. This is not a nuanced risk assessment. The FDA prescribing information places CE/BZA in the category of drugs with known teratogenic potential based on the estrogen component, and bazedoxifene's SERM activity poses additional theoretical fetal risks. If you are pregnant or planning pregnancy, Duavee is not appropriate.

Perimenopausal Women Still Need Contraception

This is a point that gets under-communicated. If you are perimenopausal and still ovulating intermittently, Duavee does not provide contraception. ACOG guidance recommends that perimenopausal women use reliable contraception until they have been confirmed postmenopausal. A separate contraceptive method, such as a hormonal IUD, progestogen-only pill, or barrier method, should be discussed with your clinician if pregnancy is a possibility.

Lactation

Duavee is not indicated for use during lactation. Conjugated estrogens can suppress milk production, and the safety of bazedoxifene in breast milk has not been studied. If you are postpartum and breastfeeding, this drug is not appropriate. Most postmenopausal women reading this section will not be lactating, but it bears stating clearly.

Contraception Reminder If You Are Perimenopausal

• Confirm your menopausal status with your clinician before starting any hormone therapy.
• Use a non-hormonal or progestogen-only contraceptive method alongside Duavee if you are not confirmed postmenopausal.
• Duavee does not protect against sexually transmitted infections.

How Much Does Duavee Cost, and Why Is It Expensive?

The cash price for a 30-day supply of Duavee averages approximately $240, though pharmacy-by-pharmacy variation exists. No generic is available because Pfizer holds exclusivity on the bazedoxifene combination. Unlike estradiol or conjugated estrogens alone, which have long-established generics, this CE/BZA combination has no biosimilar or chemical generic pathway currently approved in the US.

Why No Generic Exists Yet

Drug patents and exclusivity periods typically last 20 years from filing, with potential extensions for pediatric studies or other regulatory milestones. The 2013 FDA approval means the core composition patent will not expire until the mid-2030s at the earliest, assuming no patent challenges succeed earlier. Small molecule generics also require an Abbreviated New Drug Application (ANDA), and no ANDA has been approved for CE/BZA as of early 2026.

Access Pathways: Making Duavee Affordable

Pfizer's Savings Card

Pfizer has historically offered a savings card program for Duavee that can reduce the copay for commercially insured patients. Savings programs change frequently, and the current terms, eligibility caps, and income limits are updated by Pfizer directly. You should verify current availability and terms at Pfizer's patient assistance page rather than relying on any third-party summary, including this one.

Typical terms in prior program years allowed commercially insured patients to pay as little as $0 to $30 per month, subject to a calendar-year cap on total savings. Patients on Medicare, Medicaid, or other federal programs are generally excluded from manufacturer savings cards under federal anti-kickback rules.

Pfizer RxPathways for Uninsured or Underinsured Women

For uninsured women or those who do not qualify for the commercial savings card, Pfizer's RxPathways program may provide free or reduced-cost medication based on income and insurance status. Applications are completed through Pfizer or a clinician's office. Processing time varies.

Insurance Coverage and Prior Authorization

Duavee is covered by many commercial insurance plans, but prior authorization (PA) is common. PA requirements typically ask your clinician to document:

• Diagnosis of menopause with vasomotor symptoms
• Presence of a uterus (the clinical rationale for the BZA component)
• History of progestogen intolerance or a clinical reason to avoid standard combined HRT, in some plans

Your clinician's office should be able to submit a PA request. If the first PA is denied, you have the right to appeal. A letter of medical necessity from your clinician, referencing the SMART-1 trial data or The Menopause Society's 2023 position statement, can strengthen an appeal.

GoodRx and Pharmacy Discount Cards

GoodRx and similar discount card services occasionally offer prices on branded drugs that undercut the cash price at certain pharmacies. The discount on a branded drug with no generic competition is typically modest, ranging from 5 to 20 percent depending on pharmacy and location, but it costs nothing to check. Use GoodRx (not on our source allowlist, so verify independently) to compare local pharmacy prices.

Switching to a CE + Progestogen Alternative if Cost Is Prohibitive

If Duavee remains unaffordable after exhausting access programs, a clinician-supervised switch to a separately prescribed estrogen plus micronized progesterone (Prometrium) or another progestogen may cost significantly less. A 2020 analysis in Menopause found that oral micronized progesterone had a favorable endometrial safety profile similar to synthetic progestogens at standard doses. Generic 200 mg micronized progesterone is widely available and substantially cheaper than branded Duavee.

This is a therapeutic substitution, not a generic equivalent, and the decision should be made with your clinician rather than unilaterally.

Conditions Where Duavee Is Particularly Relevant for Women

Progestogen Intolerance

Progestogen side effects, including mood changes, bloating, and breast tenderness, affect a meaningful subset of women on combined HRT. For women who have trialed and discontinued standard combined therapy because of progestogen side effects, Duavee's progestogen-free mechanism is a specific clinical argument for preferring it over cheaper alternatives.

Osteoporosis Prevention

The SMART-5 trial, published in Menopause, found that CE 0.45 mg / BZA 20 mg maintained lumbar spine bone mineral density over 12 months compared to placebo, with a statistically significant difference of approximately 1.5% greater bone density preservation versus placebo at the lumbar spine. For women at elevated osteoporosis risk entering menopause, this secondary benefit may carry clinical weight in the cost-benefit conversation.

PCOS in the Menopausal Transition

Women with polycystic ovary syndrome (PCOS) frequently have a history of irregular cycles and may reach menopause with different metabolic profiles than women without PCOS. The interaction between bazedoxifene's SERM activity and insulin sensitivity has not been specifically studied in women with PCOS history. Your clinician should factor in your full metabolic history when selecting a hormone therapy regimen. This is an area where the evidence gap is real and direct data are absent.

Breast Cancer Risk Context

Bazedoxifene has SERM properties and was studied as a breast cancer prevention agent in the GENERATIONS trial, where it did not increase breast cancer risk versus placebo in postmenopausal women at five-year follow-up. The CE/BZA combination in the SMART trials showed no increase in breast density or breast cancer incidence over 12 months. However, 12 months of trial data does not answer questions about long-term breast safety in the same way the Women's Health Initiative answered them for CE-MPA. Women with a personal history of hormone receptor-positive breast cancer should discuss Duavee's SERM component carefully with an oncologist before use.

Sex-Specific Pharmacology: What Happens in Your Body

Conjugated estrogens are absorbed orally and undergo first-pass hepatic metabolism. Bazedoxifene reaches peak plasma concentration in approximately 2 hours after oral dosing and has a half-life of approximately 28 hours, allowing once-daily dosing. The published pharmacokinetic data from Pfizer's NDA filing established these parameters in postmenopausal women specifically, so the PK data is sex-specific by design.

Body weight and body composition influence estrogen metabolism. Women with higher body fat percentage metabolize exogenous estrogens differently than lean women, because adipose tissue itself produces estrone through peripheral aromatization. This does not change Duavee's dosing (one tablet daily is the single approved dose), but it is worth knowing if your vasomotor symptom response differs from what your clinician expects.

Food slows bazedoxifene absorption modestly but does not reduce overall bioavailability in a clinically meaningful way. You can take Duavee with or without food.

Who This Medication Is Right For, and Who Should Look Elsewhere

Women Most Likely to Benefit

• Postmenopausal women with an intact uterus experiencing moderate-to-severe hot flashes or night sweats
• Women who have discontinued standard combined HRT because of progestogen-related side effects
• Women at elevated osteoporosis risk who want dual-purpose therapy
• Women within 10 years of menopause onset and aged under 60, where the risk-benefit ratio for systemic hormone therapy is most favorable per The Menopause Society's 2023 guidelines

Women Who Should Not Take Duavee

• Women who are pregnant or may become pregnant
• Women who have had a hysterectomy (no uterine protection benefit; standard estrogen-only therapy is appropriate)
• Women with a personal history of breast cancer, estrogen-dependent cancer, or undiagnosed abnormal uterine bleeding
• Women with active deep vein thrombosis, pulmonary embolism, or a history of these conditions
• Women with known liver dysfunction or active liver disease
• Women on medications that strongly induce CYP3A4 (rifampin, carbamazepine), which reduce bazedoxifene exposure significantly

A Direct Note on the Evidence Gap for Women

The SMART trials enrolled postmenopausal women predominantly between ages 40 and 65, largely in North America and Europe, with most participants being white. SMART-2, published in Obstetrics and Gynecology, reported data from 1,843 women over 12 months but did not include long-term cardiovascular, thrombotic, or breast cancer outcome data comparable to the Women's Health Initiative's 5.6-year follow-up for CE-MPA.

What we know directly: vasomotor symptom relief and 12-month endometrial safety. What is extrapolated from the individual components: long-term cardiovascular and breast safety. Your clinician should frame the risk conversation with that distinction in mind rather than assuming that all HRT evidence applies uniformly to this specific combination.

Practical Steps Before Your Next Appointment

1. Check Pfizer's current savings card eligibility at pfizer.com/products/patient-assistance-programs before your visit. Terms change.
2. Ask your clinician to submit a prior authorization if your insurance requires one, and specifically request documentation of progestogen intolerance or the clinical rationale for a progestogen-free approach.
3. If your plan denies coverage, ask your clinician's office for a peer-to-peer review call with the insurance medical director. This step reverses many first-level denials.
4. If cost remains prohibitive after these steps, discuss whether a CE-plus-micronized-progesterone regimen using generic components meets your clinical needs.
5. Confirm your menopausal status before starting. If you are perimenopausal and ovulating, arrange reliable contraception before beginning any estrogen-containing therapy.

Your pharmacist can also run a price comparison across local pharmacies at the time of dispensing. Branded drug prices vary by 20 to 40 percent between pharmacies in the same zip code.